Phase II Study in Fragile X Syndrome -- IND clearance received from FDA; first patient enrollment targeted by year-end with ...
Bile Acid Medicines Sales -- $41 million attributed to CHOLBAM and CTEXLI medicines supported by expanded CTX patient finding ...
Q4 2025 Earnings Call March 31, 2026 4:00 PM EDTCompany ParticipantsWilliam Li - President, CEO & ChairmanApoorv Dwivedi ...
Analyst/Investor Day March 31, 2026 12:00 PM EDTCompany ParticipantsAnoori Naughton - Vice President of Investor ...
Origin Materials, Inc. (NASDAQ:ORGN) Q4 2025 Earnings Call Transcript March 27, 2026 Origin Materials, Inc. misses on ...
In 1999, a 13-year-old girl was found dead in the Bronx. Then the trail went cold for 20 years, until an ingenious ploy by ...
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation ...
AI tools infused with faculty expertise are intended to help students think through solutions while exploring and refining ...
Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
Redesigning learning experiences, not just adding tools, can build faculty confidence and develop students’ critical, ethical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results